Synovus Financial Corp Has $5.94 Million Position in Novo Nordisk A/S (NYSE:NVO)

Synovus Financial Corp boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,094 shares of the company's stock after buying an additional 14,397 shares during the period. Synovus Financial Corp's holdings in Novo Nordisk A/S were worth $5,944,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Passumpsic Savings Bank boosted its stake in Novo Nordisk A/S by 0.9% during the 3rd quarter. Passumpsic Savings Bank now owns 21,448 shares of the company's stock valued at $2,554,000 after purchasing an additional 194 shares during the period. Virtu Financial LLC grew its holdings in Novo Nordisk A/S by 69.8% in the 3rd quarter. Virtu Financial LLC now owns 33,929 shares of the company's stock worth $4,040,000 after buying an additional 13,949 shares in the last quarter. Tudor Financial Inc. acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at approximately $311,000. Anchor Investment Management LLC raised its stake in Novo Nordisk A/S by 2.3% during the 3rd quarter. Anchor Investment Management LLC now owns 13,447 shares of the company's stock valued at $1,601,000 after acquiring an additional 297 shares in the last quarter. Finally, World Investment Advisors LLC boosted its position in Novo Nordisk A/S by 36.9% during the 3rd quarter. World Investment Advisors LLC now owns 13,925 shares of the company's stock worth $1,655,000 after acquiring an additional 3,750 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $4.48 during trading on Thursday, hitting $58.40. The company had a trading volume of 21,130,515 shares, compared to its average volume of 5,911,789. The company has a market cap of $262.08 billion, a P/E ratio of 17.76, a PEG ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business's 50-day moving average is $76.55 and its 200 day moving average is $92.55. Novo Nordisk A/S has a 52 week low of $57.36 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 49.54%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday. They set an "underperform" rating on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.